We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

12 hedge funds and large institutions have $7.63M invested in Traws Pharma in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

28% more capital invested

Capital invested by funds: $5.97M → $7.63M (+$1.67M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 0.13% → 0.11% (-0.02%)

25% less funds holding

Funds holding: 16 → 12 (-4)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Holders
12
Holders Change
-4
Holders Change %
-25%
% of All Funds
0.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
2
Reduced
1
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$61.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$28.5K
3
PFGIA
Patriot Financial Group Insurance Agency
Massachusetts
+$5.94K
4
UBS Group
UBS Group
Switzerland
+$5.94K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$893K
2
SM
Sabby Management
Florida
-$101K
3
AC
Armistice Capital
New York
-$62K
4
OAM
Oxford Asset Management
United Kingdom
-$32K
5
BCM
Bridgeway Capital Management
Texas
-$30K
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
1
683 Capital Management
New York
$3.19M – – –
TCP
2
Tyndall Capital Partners
New York
$2.69M – – –
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$798K – – –
KC
4
Kepos Capital
New York
$423K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$154K -$1.19K -1 -0.8%
Vanguard Group
6
Vanguard Group
Pennsylvania
$135K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$115K +$28.5K +24 +34%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$107K +$61.8K +52 +149%
PFGIA
9
Patriot Financial Group Insurance Agency
Massachusetts
$7K +$5.94K +5 New
UBS Group
10
UBS Group
Switzerland
$6K +$5.94K +5 New
Morgan Stanley
11
Morgan Stanley
New York
$2K – – –
WCG
12
Weaver Consulting Group
California
$1K +$1.19K +1 New
EC
13
EcoR1 Capital
California
– -$893K -1,129 Closed
SM
14
Sabby Management
Florida
– -$101K -127 Closed
AC
15
Armistice Capital
New York
– -$62K -78 Closed
OAM
16
Oxford Asset Management
United Kingdom
– -$32K -40 Closed
BCM
17
Bridgeway Capital Management
Texas
– -$30K -38 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$29K -37 Closed
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
– -$8K -10 Closed

TRAW Hedge Fund Activity: Q1 2019 in Review

12 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2019, worth a combined $7.63M — up 28% from $5.97M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRAW and 3 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $61.8K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $893K sold.

  • 12 institutional investors held Traws Pharma (TRAW) as of Q1 2019, down from 16 in Q4 2018.
  • Funds reported $7.63M of Traws Pharma stock for Q1 2019, up 28% quarter-over-quarter.
  • 3 funds opened new Traws Pharma positions in Q1 2019 and 7 closed out, a net change of -4 holders.
  • The largest Traws Pharma buyer in Q1 2019 was Dimensional Fund Advisors, an estimated $61.8K added.
  • The largest Traws Pharma seller in Q1 2019 was EcoR1 Capital, an estimated $893K sold.

Based on aggregated 13F filings for Q1 2019.